Related Articles Death, Dying, and Dignity in the Time of the COVID-19 Pandemic. J Palliat Med. 2020 10;23(10):1294-1295 Authors: Chochinov HM, Bolton J, Sareen J PMID: 32639895 [PubMed – indexed for MEDLINE]
Origen: Death, Dying, and Dignity in the Time of the COVID-19 Pandemic. – PubMed

COVID-19 – A Review of the Impact it has made on Supportive and Palliative Care Services Within a Tertiary Hospital and Cancer Centre in Singapore. Ann Acad Med Singap. 2020 07;49(7):489-495 Authors: Ho S, Tan YY, Neo SHS, Zhuang Q, Chiam M, Zhou JX, Woong NL, Lee G, Krishna LKR PMID: 33000112 [PubMed – indexed for MEDLINE]
Origen: COVID-19 – A Review of the Impact it has made on Supportive and Palliative Care Services Within a Tertiary Hospital and Cancer Centre in Singapore. – PubMed

Palliative Care in a COVID-19 Intensive Care Unit (ICU): Challenges and Recommendations for Palliative Care Teams in a Pandemic ICU. Ann Acad Med Singap. 2020 07;49(7):517-522 Authors: Poi CH, Koh MY, Neo HY, Hum AY PMID: 33000118 [PubMed – indexed for MEDLINE]
Origen: Palliative Care in a COVID-19 Intensive Care Unit (ICU): Challenges and Recommendations for Palliative Care Teams in a Pandemic ICU. – PubMed

Related Articles Unexpected response with palliative conventional therapy in head and neck squamous cell carcinoma after anti-programmed death-1 progression. Head Neck. 2019 03;41(3):E42-E47 Authors: Denaro N, Merlano MC Abstract BACKGROUND: The application of anti-programmed death-1 (PD-1) therapies for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) has found promising results. It is the first «second-line therapy» in this setting to impact on prognosis. The studies demonstrated overall response rates in the range of 20%. Therefore, HNSCC showed 60%-80% progression at first evaluation with better overall survival, suggesting regained efficacy of treatments given thereafter. METHODS: We report three clinical…
Origen: Unexpected response with palliative conventional therapy in head and neck squamous cell carcinoma after anti-programmed death-1 progression. – PubMed

Related Articles Prescribing in Chronic Severe Hepatic Impairment. J Pain Symptom Manage. 2019 09;58(3):515-537 Authors: Wilcock A, Charlesworth S, Prentice W, Selby P, McKenna M, Cripps S, Considine A, Orr A, Wright M, Mihalyo M, Oxberry S Abstract Therapeutic Reviews aim to provide essential independent information for health professionals about drugs used in palliative and hospice care. Additional content is available via www.palliativedrugs.com. The series editors welcome feedback on the articles. PMID: 31077785 [PubMed – indexed for MEDLINE]
Origen: Prescribing in Chronic Severe Hepatic Impairment. – PubMed